Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Jun 30, 2017
Mar 31, 2017
Dec 31, 2016
Sep 30, 2016
Total Revenue
317,448
303,745
300,091
279,896
Cost of Revenue
56,305
50,006
64,147
50,738
Gross Profit
261,143
253,739
235,944
229,158
Operating Expenses
Research Development
143,039
145,003
175,242
160,831
Selling General and Administrative
143,505
120,019
142,958
118,758
Non Recurring
--
--
--
--
Others
13,411
8,925
7,365
9,654
Total Operating Expenses
299,955
273,947
325,565
289,243
Operating Income or Loss
(38,812)
(20,208)
(89,621)
(60,085)
Income from Continuing Operations
Total Other Income/Expenses Net
(7,523)
(4,751)
4,261
1,619
Earnings Before Interest And Taxes
(43,352)
(21,887)
(82,434)
(56,833)
Interest Expense
2,194
2,419
9,732
9,980
Income Before Tax
(45,546)
(24,306)
(92,166)
(66,813)
Income Tax Expense
(8,713)
(8,016)
(13,455)
(24,016)
Minority Interest
--
--
--
--
Net Income From Continuing Ops
(36,833)
(16,290)
(78,711)
(42,797)
Non-recurring Events
Discontinued Operations
--
--
--
--
Extraordinary Items
--
--
--
--
Effect Of Accounting Changes
--
--
--
--
Other Items
0
0
0
0
Net Income
(36,833)
(16,290)
(78,711)
(42,797)
Preferred Stock And Other Adjustments
--
--
--
--
Net Income Applicable To Common Shares
(36,833)
(16,290)
(78,711)
(42,797)

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information